newsfilter
← Latest News
Business Wire·

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

Demonstrated combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies Data highlights efficacy of ‘539 in a preclinical AML model, with limited impact on platelet levels Identified PD